ABC | Volume 113, Nº5, November 2019

Original Article Congo et al. New-Onset atrial fibrillation in STEMI Arq Bras Cardiol. 2019; 113(5):948-957 Table 4 – Medical therapy at discharge All Group 1 – No AF Group 2 – New onset AF p Aspirin 96.2 96.3 93.1 0.005 Clopidogrel 80.3 80.2 81.3 0.634 Ticagrelor 19.3 19.6 13.7 0.065 Prasugrel 0.3 0.3 0 1.000 Other AP 4.9 5.0 3.6 0.289 Vitamin K antagonists 2.4 1.9 11.2 < 0.001 NOACs 1.2 0.8 7.9 < 0.001 Beta-blockers 81.6 82.2 71.1 < 0.001 ACE inhibitors/ARB 87.7 88.0 81.3 < 0.001 Aldosterone antagonists 12.0 11.2 26.0 < 0.001 Diuretics 20.1 18.7 46.6 < 0.001 Amiodarone 2.4 1.1 26.4 < 0.001 Other antiarrhythmic drugs 0.1 0.1 0 1.000 Digitalis 0.4 0.2 4.0 < 0.001 Values are percentage (%). AF: atrial fibrillation; NOAC: non vitamin K anticoagulant. Table 5 – Patients from group 2 on triple therapy Antithrombotic therapy Group 2 – New onset AF Aspirin + Clopidogrel + Vitamin K antagonists 10.2 Aspirin + Clopidogrel + NOACs 5.9 Aspirin + Ticagrelor/Prasugrel + Vitamin K antagonists 0 Aspirin + Ticagrelor/Prasugrel + NOACs 0 Total 16.1 Values are percentage (%). AF: atrial fibrillation; ACE inhibitors: angiotensin conversion enzyme inhibitors; ARB: angiotensin receptor blockers; NOAC: non vitamin K anticoagulant. Table 6 – In-hospital complications All Group 1 – No AF Group 2 – New onset AF p LV Ejection fraction < 50% 43.4 42.2 62.1 p < 0.001 Heart failure 16.8 14.9 48.5 p < 0.001 Cardiogenic shock 5.9 4.9 22.3 p < 0.001 Atrioventricular block 5.3 4.8 14.2 p < 0.001 Ventricular tachycardia 2.6 2.1 10.7 p < 0.001 Cardiac arrest 5.2 4.8 11.8 p < 0.001 Mechanical complications 1.3 1.2 3.3 p = 0.002 Stroke 0.7 0.6 2.5 p = 0.001 Major bleeding 1.9 1.6 6.8 p < 0.001 Values are percentage (%). AF: atrial fibrillation; LV: left ventricular 953